Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Angiotech Pharmaceuticals, Inc.

http://www.angiotech.com

Latest From Angiotech Pharmaceuticals, Inc.

First Generic Of B+L’s OTC Switch Lumify Approved For Dr. Reddy’s Amid Patent Infringement Battle

Canadian firm received approval from FDA for NDA submitted in May 2023 for Lumify Preservative Free. A month earlier, FDA approved Dr. Reddy's ANDA submitted in July 2021 for an equivalent of Lumify’s formulation, brimonidine tartrate 0.025% ophthalmic solution.

Prescription To OTC Switch Patents

Digital Health Roundup: US FDA’s ‘Idea Lab’; Philips’ Roy Jakobs On AI Draft Framework; Apple Watch

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights key interviews with Philips’ CEO Roy Jakobs on NAM’s framework on AI, BD’s CTO Beth McCombs R&D initiatives and HSS spine co-chair Sheeraz Qureshi on his vision for integrating AI tech. Hannah Daniel discusses the FDA’s new initiative to create an idea lab for medical device use at home and a new feature on the Apple Watch to help people with Parkinson's disease overcome freezing gait.   

Digital Health Approvals

Cash-Rich SynOx Well Placed To Compete In Hot TGCT Field

Ono’s just-announced purchase of Deciphera has put the tenosynovial giant cell tumor space under the spotlight and SynOx is making strides to stay at the head of the pack helped by significant financing.

Financing Business Strategies

Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?

The US FDA’s observations at its radiopharma manufacturing facility in Canada could be a headwind for Jubilant Pharmova, but reorientation of US generics manufacturing is expected to boost profits. Scrip takes a look at the likely impact.

Manufacturing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
    • Consumables, Central Supplies
    • Implantable Devices
    • Infection Control-Sterilization
    • Infusion Therapy Equipment and Supplies
    • Laser
    • Monitoring Equipment & Devices
    • Radiofrequency Devices
    • Rehabilitation Equipment and Devices
    • Surgical Equipment & Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Other Names / Subsidiaries
    • Quill Medical Inc.
    • Surgical Specialties Corporation, Inc.
UsernamePublicRestriction

Register